Skip to Content
Upcoming Webinar

Repotrectinib (Augtyro®) in Patients with ROS1 Fusion-Positive NSCLC: Data from the Pivotal Phase 1/2 TRIDENT-1 Trial

Date: December 4, 2025 | 2:00 PM
When: Thursday, December 4 | 2 p.m. EST
Presenters:
Magda Dankowska, PharmD, BCOP | Bristol Myers Squibb

Repotrectinib is quickly becoming a key consideration for patients with ROS1 fusion–positive NSCLC—and the TRIDENT-1 trial offers some of the clearest evidence yet on where it may fit in practice.

Magda Dankowska will take a clinically focused look at this next-generation TKI and what the data means for real-world treatment decisions.

Learn about:

  • The mechanism of action behind repotrectinib and its clinical rationale
  • Efficacy and safety outcomes from the pivotal Phase 1/2 TRIDENT-1 trial
  • How repotrectinib’s clinical profile compares with other ROS1-targeted options
  • Practical implications for sequencing and patient selection in oncology care

For additional information or login assistance, reach out to NCODA’s Jonathan Rivera.